BioMed Research International / 2018 / Article / Tab 1 / Review Article
The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Table 1 Characteristics of studies included in this meta-analysis.
Study and group Median age Induction regimen Maintenance regimen Number of enrolled Male (%) Stage of disease J. Patel (2013) [11 ] Intervention arm 65 (Pem)500mg/m2, (C)AUC6, (Bev)15mg/kg four 21-day cycles (Pem)500 mg/m2, (Bev) 15 mg/kg 472 251(53.2%) IIIB IV Control arm 65 (Pac) 200 mg/m2, (C)AUC6, (Bev) 15mg/kg four 21-day cycles (Bev) 15 mg/kg 467 249(53.3%) F. Barlesi (2013) [12 ] Intervention arm 60 (Pem)500mg/m2 (Bev)7.5 mg/kg, (Cis)75mg/m2 four 21-day cycles (Pem)500mg/m2 (Bev)7.5 mg/kg, 128 72(57.6%) IIIB IV Control arm 60 (Pem)500mg/m2 (Bev)7.5 mg/kg, (Cis)75mg/m2 four 21-day cycles (Bev)7.5 mg/kg 125 68(56.7%) M. Karayama (2016) [13 ] Intervention arm 65 (Pem)500mg/m2, (C)AUC6, (Bev)15mg/kg four 21-day cycles (Pem)500 mg/m2, (Bev) 15 mg/kg 55 35(63.6%) IIIB IV Control arm 66 (Pem)500mg/m2, (C)AUC6, (Bev)15mg/kg four 21-day cycles (Pem)500 mg/m2 55 39(70.9%)
Pem, pemetrexed; Bev, bevacizumab; C, carboplatin; Pac, paclitaxel; Cis, cisplatin; AUC, area under the serum concentration-time curve